EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A

By SquaredTown on November 12, 2025

TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast...

Read More